Literature DB >> 7833883

[Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients].

P Le Guennec1, C Dromer, L Sixou, V Marc, P Coustals, B Fournié.   

Abstract

Thirty-six patients with giant cells arteritis were studied retrospectively. Histological examination of the temporal artery or another artery was positive in 95% of cases. Mean follow-up was five years. A synthetic antimalarial was used in every case. Two groups were differentiated. One (Group I) was composed of 21 patients who were given the antimalarial drug as part of the first-line therapy, either with a corticosteroid in a mean dose of 36 mg/d (18 patients) or with a nonsteroidal antiinflammatory agent. The other group (Group II) included 15 patients in whom the antimalarial was used after a period of corticosteroid therapy, because of steroid-dependency (n = 5) or adverse effects (n = 9), or as part of a routinely used protocol (n = 1). Withdrawal of the corticosteroid was achieved in 81% of cases, after a mean interval of 15 months. Many patients discontinued the corticosteroid after less than one year. The 18 Group I patients who were given a corticosteroid were all able to discontinue this drug. The overall recovery rate was 58%; mean time to recovery was 33 months with a mean follow-up of 52 months. There were no recurrences at discontinuation of the treatment. Adverse effects of antimalarial therapy were recorded in 30.5% of patients and required discontinuation of the drug in 19%. The most often used regimen was hydroxychloroquine (40 mg/d) for at least two years and prednisone 20 to 30 mg/d for two months, in the absence of vascular complications.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7833883

Source DB:  PubMed          Journal:  Rev Rhum Ed Fr        ISSN: 1169-8330


  2 in total

Review 1.  Polymyalgia rheumatica/temporal arteritis: recent advances.

Authors:  Maria-Louise Barilla-LaBarca; Deborah J Lenschow; Richard D Brasington
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 2.  [Current therapeutic options for giant cell arteritis].

Authors:  E Wipfler-Freissmuth; J Loock; F Moosig; C Dejaco; C Duftner; M Schirmer
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.